Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerius dose-response study in chronic idiopathic urticaria
2006-001449-33Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of desloratadine in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Merck & Co. Primary endpoint: Change in urticaria activity score from baseline to week 4. Started Mar 2007; status: completed.
02
Drugs
desloratadine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2006-001449-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001449-33.